Galectin Therapeutics (GALT) Cash & Equivalents (2010 - 2026)

Galectin Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 89.75% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (up 89.75% YoY), while the FY2025 annual figure was $17.7 million, up 17.2% from the prior year.
• Cash & Equivalents was $14.1 million for Q1 2026 at Galectin Therapeutics, down from $17.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $31.6 million in Q1 2022 to a low of $7.4 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $19.3 million across 5 years, with a median of $18.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 68.45% in 2025, then soared 89.75% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $18.6 million in 2022, then soared by 38.02% to $25.7 million in 2023, then tumbled by 41.08% to $15.1 million in 2024, then rose by 17.2% to $17.7 million in 2025, then fell by 20.43% to $14.1 million in 2026.
• The last three Cash & Equivalents figures came in at $14.1 million (Q1 2026), $17.7 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.